Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

Journal of Experimental Medicine

Volumn 204, Issue 13, 2007, Pages 3183-3194

  Zaba, Lisa C ^a   Cardinale, Irma ^a   Gilleaudeau, Patricia ^a   Sullivan Whalen, Mary ^a   Fariñas, Mayte Suárez ^a   Fuentes Duculan, Judilyn ^a   Novitskaya, Inna ^a   Khatcherian, Artemis ^a   Bluth, Mark J ^b   Lowes, Michelle A ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 4; CC CHEMOKINE LIGAND 20; CHEMOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; LYMPHOTOXIN; MYXOVIRUS RESISTANCE PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DENDRITIC CELL; EPIDERMIS HYPERPLASIA; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; TH1 CELL;

DENDRITIC CELLS; EPIDERMIS; HUMANS; HYPERPLASIA; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-23; KI-67 ANTIGEN; MACROPHAGES; MODELS, BIOLOGICAL; MYELOID CELLS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37549011317     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20071094     Document Type: Article

References (50)

1. Lowes, M.A., A.M. Bowcock, and J.G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature. 445:866-873.
2. Blauvelt, A. 2007. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev. Dermatol. 2:69-78.
3. Prinz, J.C., B. Grob, S. Vollmer, P. Trommler, I. Strobel, M. Meurer, and G. Plewig. 1994. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immunol. 24:593-598.
4. Bettelli, E., M. Oukka, and V.K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345-350.
5. Liang, S.C., X.Y. Tan, D.P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, M. Collins, and L.A. Fouser. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271-2279.
6. Wolk, K., E. Witte, E. Wallace, W.D. Docke, S. Kunz, K. Asadullah, H.D. Volk, W. Sterry, and R. Sabat. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36:1309-1323.
7. Zheng, Y., D.M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 445:648-651.
8. Sa, S.M., P.A. Valdez, J. Wu, K. Jung, F. Zhong, L. Hall, I. Kasman, J. Winer, Z. Modrusan, D.M. Danilenko, and W. Ouyang. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178:2229-2240.
9. Mangan, P.R., L.E. Harrington, D.B. O'Quinn, W.S. Helms, D.C. Bullard, C.O. Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, and C.T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231-234.
10. Sutton, C., C. Brereton, B. Keogh, K.H. Mills, and E.C. Lavelle. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203:1685-1691.
11. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Fili, S. Ferri, F. Frosali, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:1849-1861.
12. Vanden Eijnden, S., S. Goriely, D. De Wit, F. Willems, and M. Goldman. 2005. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur. J. Immunol. 35:469-475.
13. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177:566-573.
14. Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 17:375-387.
15. Park, H., Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-1141.
16. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173-6177.
17. Uyttenhove, C., and J. Van Snick. 2006. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 36:2868-2874.
18. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M.A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316.
19. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65-70.
20. Nielsen, O.H., I. Kirman, N. Rudiger, J. Hendel, and B. Vainer. 2003. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38:180-185.
21. te Velde, A.A., F. de Kort, E. Sterrenburg, I. Pronk, F.J. ten Kate, D.W. Hommes, and S.J. van Deventer. 2007. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm. Bowel Dis. 13:325-330.
22. Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M.T. Gillespie, et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352.
23. Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, Y. Kaneko, K. Hiromura, K. Ueki, and Y. Nojima. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52:1037-1046.
24. Li, J., D. Li, and Z. Tan. 2004. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24:294-296.
25. Arican, O., M. Aral, S. Sasmaz, and P. Ciragil. 2005. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005:273-279.
26. Piskin, G., R.M. Sylva-Steenland, J.D. Bos, and M.B. Teunissen. 2006. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176:1908-1915.
27. Lee, E., W.L. Trepicchio, J.L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J.G. Krueger. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:125-130.
28. Tyring, S., A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, A. Wang, D. Lalla, M. Woolley, A. Jahreis, R. Zitnik, et al. 2006. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 367:29-35.
29. Papp, K.A., S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, R. Zitnik, P.C. van de Kerkhof, and L. Melvin. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152:1304-1312.
30. Gottlieb, A.B., F. Chamian, S. Masud, I. Cardinale, M.V. Abello, M.A. Lowes, F. Chen, M. Magliocco, and J.G. Krueger. 2005. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175:2721-2729.
31. Scott, D.L., and G.H. Kingsley. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355:704-712.
32. Atzeni, F., M. Turiel, F. Capsoni, A. Doria, P. Meroni, and P. Sarzi-Puttini. 2005. Autoimmunity and anti-TNF-alpha agents. Ann. NY Acad. Sci. 1051:559-569.
33. Furst, D.E., R. Wallis, M. Broder, and D.O. Beenhouwer. 2006. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36:159-167.
34. Lugering, A., M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, and T. Kucharzik. 2001. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 121:1145-1157.
35. Shen, C., G.V. Assche, S. Colpaert, P. Maerten, K. Geboes, P. Rutgeerts, and J.L. Ceuppens. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21:251-258.
36. Malaviya, R., Y. Sun, J.K. Tan, A. Wang, M. Magliocco, M. Yao, J.G. Krueger, and A.B. Gottlieb. 2006. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol. 55:590-597.
37. Serbina, N.V., T.P. Salazar-Mather, C.A. Biron, W.A. Kuziel, and E.G.P. Am. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 19:59-70.
38. Kao, C.Y., Y. Chen, P. Thai, S. Wachi, F. Huang, C. Kim, R.W. Harper, and R. Wu. 2004. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173:3482-3491.
39. Teunissen, M.B., C.W. Koomen, R. de Waal Malefyt, E.A. Wierenga, and J.D. Bos. 1998. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111:645-649.
40. Conrad, C., O. Boyman, G. Tonel, A. Tun-Kyi, U. Laggner, A. de Fougerolles, V. Kotelianski, H. Gardner, and F.O. Nestle. 2007. alpha(1)beta(1) integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13:836-842.
41. Gudjonsson, J.E., A. Johnston, H. Sigmundsdottir, and H. Valdimarsson. 2004. Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135:1-8.
42. Lew, W., E. Lee, and J.G. Krueger. 2004. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br. J. Dermatol. 150:668-676.
43. Nakae, S., Y. Iwakura, H. Suto, and S.J. Galli. 2007. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol. 81:1258-1268.
44. Chamian, F., M.A. Lowes, S.L. Lin, E. Lee, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA. 102:2075-2080.
45. Dhodapkar, K.M., J. Krasovsky, B. Williamson, and M.V. Dhodapkar. 2002. Antitumor monoclonal antibodies enhance cross-presentation of-cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195:125-133.
46. Zaba, L.C., J. Fuentes-Duculan, R.M. Steinman, J.G. Krueger, and M.A. Lowes. 2007. Normal human dermis contains distinct populations of CD11cBDCA-1 dendritic cells and CD163FXIIIA macrophages. J. Clin. Invest. 117:2517-2525.
47. Vugmeyster, Y., T. Kikuchi, M.A. Lowes, K. Howell, F. Chamian, M.H. Kagen, P. Gilleaudeau, E. Lee, W. Dummer, S. Pippig, et al. 2004. Efalizumab (anti-CD11a)-induced increase in leukocyte numbers in psoriasis patients is preferentially mediated by blocked entry of memory CD8+ T cells into the skin. Clin. Immunol. 113:38-46.
48. Zhou, X., J.G. Krueger, M.C. Kao, E. Lee, F. Du, A. Menter, W.H. Wong, and A.M. Bowcock. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics. 13:69-78.
49. Wittkowski, K.M., and X. Liu. 2002. A statistically valid alternative to the TDT. Hum. Hered. 54:157-164.
50. Guttman-Yassky, E. 2007. Atopic dermatitis. Curr. Probl. Dermatol. 35:154-172.